According to a study carried out in Israel, the Pfizer / BioNTech vaccine is 97% effective against symptomatic cases and severe forms of Covid-19.

These findings improve on the lessons of a previous study conducted in real conditions on vaccinated people, already in Israel. 

The Pfizer / BioNTech vaccine is 97% effective against symptomatic cases and severe forms of Covid-19, according to a real-life study carried out in Israel and published Thursday, which improves already known data on the properties of this vaccine.

Drawn from data on people vaccinated in Israel, "the results represent the most comprehensive concrete evidence to date demonstrating the effectiveness of a vaccine against Covid-19," according to a statement from Pfizer / BioNTech laboratories and the Israeli ministry of Health.

>> LIVE

- Coronavirus: follow the evolution of the situation Thursday March 11

According to the study based on the period January 17 to March 6, the vaccine is also "94%" effective against asymptomatic forms of the virus. 

Improved results compared to a previous study 

These findings improve on the lessons of a previous real-world study of people vaccinated in Israel, which found Pfizer's vaccine to be 94% effective against symptomatic cases of Covid-19.

These new findings "may be important for all countries around the world as they move forward with their own vaccination campaigns a year after the World Health Organization called Covid-19 a pandemic," add Pfizer / BioNTech. 

CORONAVIRUS ESSENTIALS

> Covid-19: is there really a risk of contamination outside?

> Coronavirus: why can a PCR test be positive one month after infection?

> Are private parties really prohibited with the curfew?

> The English variant would cause slightly different symptoms

> Audio, webcams ... When technology adapts to teleworking

Thanks to an agreement with the pharmaceutical giant Pfizer, the Hebrew state can count on a rapid supply of vaccines in exchange for biomedical data concerning their effect on its population.

This agreement has so far made it possible to administer at least a first dose of vaccine to more than half of the 9.3 million inhabitants and to conduct large-scale tests that have confirmed the effectiveness of the Pfizer / BioNtech vaccine.